OMX Copenhagen 20
|
1 499,10
|
28,42
|
1,93 %
|
Analysen zu OMX Copenhagen 20-Werten
| 04.12.24 | A.P. Moeller - Maersk A-S Underweight | JP Morgan Chase & Co. | |
| 03.12.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 02.12.24 | Novo Nordisk Neutral | UBS AG | |
| 01.12.24 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 27.11.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 27.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 18.11.24 | Novo Nordisk Neutral | UBS AG | |
| 15.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 14.11.24 | A.P. Moeller - Maersk A-S Neutral | Goldman Sachs Group Inc. | |
| 13.11.24 | Novo Nordisk Neutral | UBS AG | |
| 11.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 11.11.24 | Novo Nordisk Neutral | UBS AG | |
| 11.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 11.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 08.11.24 | Novo Nordisk Overweight | Barclays Capital | |
| 07.11.24 | Novo Nordisk Neutral | UBS AG | |
| 07.11.24 | Novo Nordisk Halten | DZ BANK | |
| 07.11.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 07.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 06.11.24 | Novo Nordisk Neutral | UBS AG | |
| 06.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 06.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 06.11.24 | Novo Nordisk Neutral | UBS AG | |
| 06.11.24 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 04.11.24 | Novo Nordisk Neutral | UBS AG | |
| 04.11.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 04.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 01.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 31.10.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 31.10.24 | A.P. Moeller - Maersk A-S Neutral | UBS AG | |
| 30.10.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 28.10.24 | Novo Nordisk Neutral | UBS AG | |
| 22.10.24 | Novo Nordisk Halten | DZ BANK | |
| 21.10.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 21.10.24 | Novo Nordisk Underperform | Bernstein Research | |
| 17.10.24 | A.P. Moeller - Maersk A-S Neutral | UBS AG | |
| 15.10.24 | Novo Nordisk Neutral | UBS AG | |
| 10.10.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 03.10.24 | Novo Nordisk Neutral | UBS AG | |
| 27.09.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. |